Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open-Label, Dose- Escalation Trial of ACY-1215 in Combination With Gemcitabine and Cisplatin in Patients With Unresectable or Metastatic Cholangiocarcinoma

NCT02856568 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02856568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02856568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open-Label, Dose- Escalation Trial of ACY-1215 in Combination With Gemcitabine and Cisplatin in Patients With Unresectable or Metastatic Cholangiocarcinoma
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Withdrawn
Start date
May 1, 2017
Completion date
October 31, 2021
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non-resectable cholangiocarcinoma, recurrent cholangiocarcinoma, stage iii extrahepatic bile duct cancer, stage iii intrahepatic cholangiocarcinoma, stage iiia hilar cholangiocarcinoma, stage iiib hilar cholangiocarcinoma, stage iva extrahepatic bile duct cancer, stage iva hilar cholangiocarcinoma, stage iva intrahepatic cholangiocarcinoma, stage ivb extrahepatic bile duct cancer, stage ivb hilar cholangiocarcinoma, stage ivb intrahepatic cholangiocarcinoma, unresectable extrahepatic bile duct carcinoma